TC
TARA icon

TFS Capital’s Protara Therapeutics TARA Stock Holding History

TFS Capital’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-642
Closed -$206K – 972
2016
Q2 		$206K Buy
+642
New +$192K 0.04% 721
2015
Q3 		– Sell
-528
Closed -$377K – 1033
2015
Q2 		$377K Buy
+528
New +$327K 0.04% 621

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

TFS Capital's TARA Position: Q3 2016 in Review

TFS Capital sold out of Protara Therapeutics (TARA) in Q3 2016, closing a stake of 642 shares — an estimated $206K sold.

TFS Capital first reported a position in TARA in Q2 2015 and held it in 2 quarters. The position peaked at $377K in Q2 2015. 29 funds tracked by Wall St. Rank hold TARA as of Q3 2016.

  • TFS Capital reported no remaining Protara Therapeutics position as of Q3 2016 after selling out during the quarter.
  • TFS Capital sold 642 Protara Therapeutics shares in Q3 2016, an estimated $206K.
  • TFS Capital first reported a position in Protara Therapeutics in Q2 2015 and held it in 2 quarters.
  • TFS Capital's Protara Therapeutics position peaked at $377K in Q2 2015.
  • 29 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.